Study guide
4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents
ANCC Adult-Gerontology Primary Care Nurse Practitioner AGPCNP-BC
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: The AGPCNP-BC Examination: Blueprint, Format & Scoring
1.1 The AGPCNP-BC Blueprint, Exam Format, Scoring, Eligibility & Renewal
2 Chapter 2: Assessment Foundations & Lifespan Considerations
2.1 Comprehensive Health History, Symptom Analysis & Lifespan Variations 2.2 Physical Examination Techniques & Age-Related Physiological Changes 2.3 Functional Assessment (Katz ADL / Lawton IADL) & Frailty Syndromes 2.4 Psychosocial, Nutritional, Cognitive & Mental Health Screening Instruments 2.5 Health Screening Guidelines (USPSTF) & Adult Immunization Schedules (CDC/ACIP)
3 Chapter 3: Diagnostic Reasoning & Clinical Interpretation
3.1 Diagnostic Reasoning, Clinical Decision-Making & Differential Diagnosis Formulation 3.2 Routine & Specialized Laboratory Interpretation 3.3 Diagnostic Imaging, ECG Interpretation & Pulmonary Function Testing 3.4 Evidence-Based Testing, Pre-Test Probability & Choosing Wisely Principles
4 Chapter 4: Cardiovascular Disorders
4.1 Hypertension: 2025 AHA/ACC Guideline, Resistant HTN & Secondary HTN 4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents 4.3 Coronary Artery Disease, Stable Angina & Post-ACS Outpatient Management 4.4 Heart Failure (HFrEF/HFpEF), Atrial Fibrillation & Peripheral Vascular Disease
5 Chapter 5: Respiratory Disorders
5.1 Asthma: GINA 2026 Guidelines, Phenotypes, Stepwise Pharmacotherapy & Action Plans 5.2 COPD: GOLD 2026 Report, ABE Staging, Triple Inhalers & Exacerbations 5.3 Lower Respiratory Infections (CAP, Bronchitis), Pleural Disease & Solitary Pulmonary Nodules
6 Chapter 6: HEENT & Allergic/Immunologic Disorders
6.1 Eye & Vision Disorders in Adult-Gerontology Primary Care 6.2 Ear, Hearing & Vestibular Disorders 6.3 Nose, Sinus, Oropharyngeal & Oral Cavity Disorders 6.4 Allergic & Immunologic Disorders: Anaphylaxis, Urticaria, Angioedema & Immunodeficiency
7 Chapter 7: Endocrine & Metabolic Disorders
7.1 Type 2 Diabetes Mellitus: ADA Standards of Care, Pharmacotherapy & Microvascular Complications 7.2 Thyroid Disorders: Hypothyroidism, Hyperthyroidism, Thyroiditis & Nodules 7.3 Adrenal & Pituitary Disorders: Adrenal Insufficiency, Cushing's, Hyperaldosteronism & Hypopituitarism 7.4 Metabolic Bone Disease: Osteopenia, Osteoporosis (FRAX, DEXA) & Hyperparathyroidism
8 Chapter 8: Gastrointestinal & Hepatic Disorders
8.1 Upper GI Disorders: GERD, Barrett's Esophagus, PUD, H. pylori & Gastritis 8.2 Lower GI Disorders: Irritable Bowel Syndrome (IBS), Inflammatory Bowel Disease (IBD) & Diverticular Disease 8.3 Hepatobiliary Disorders: MASLD/MASH, Viral & Alcoholic Hepatitis, Cirrhosis & Cholelithiasis 8.4 Acute & Chronic Abdominal Pain Syndromes, GI Bleeding & Colorectal Cancer Screening
9 Chapter 9: Renal, Urological & Men's Health
9.1 Chronic Kidney Disease: KDIGO Staging, Albuminuria Management & Renoprotective Strategies 9.2 Urinary Tract Infections (Uncomplicated, Complicated, Recurrent), Pyelonephritis & Microscopic Hematuria 9.3 Men's Health: Benign Prostatic Hyperplasia, Prostatitis, Epididymitis & Erectile Dysfunction
10 Chapter 10: Musculoskeletal & Rheumatologic Disorders
10.1 Degenerative & Overuse Musculoskeletal Disorders: Osteoarthritis, Tendinopathies & Spine Disorders 10.2 Autoimmune Rheumatologic Disorders: Rheumatoid Arthritis, SLE, Polymyalgia Rheumatica & Giant Cell Arteritis 10.3 Crystal Arthropathies & Fibromyalgia: Gout, Pseudogout & Centralized Pain Syndromes
11 Chapter 11: Neurological & Psychiatric Disorders
11.1 Headaches (Migraine, Tension, Cluster) & Cranial Neuralgias 11.2 Cerebrovascular Disease, TIA, Peripheral Neuropathies & Movement Disorders (Parkinson's) 11.3 Mood & Anxiety Disorders: Major Depressive Disorder, Generalized Anxiety Disorder & PTSD 11.4 Substance Use Disorders: Alcohol, Tobacco, Opioids & Cannabis in Primary Care
12 Chapter 12: Dermatologic, Hematologic & Infectious Disease
12.1 Primary Dermatologic Lesions, Inflammatory Dermatoses & Cutaneous Malignancies 12.2 Common Infectious Diseases: Skin/Soft Tissue Infections, Tick-Borne Illnesses & Viral Syndromes 12.3 Sexually Transmitted Infections (STIs): CDC Guidelines, Screening & Partner Management 12.4 Hematologic Disorders: Anemias (Microcytic, Normocytic, Macrocytic), Leukopenia & Coagulopathies
13 Chapter 13: Geriatric Syndromes, Pharmacology & Palliative Care
13.1 The Geriatric 5Ms Framework, Multimorbidity & Polypharmacy Deprescribing 13.2 Beers Criteria 2023 Update & STOPP/START Prescribing Rules 13.3 Pharmacokinetics, Pharmacodynamics & Pharmacogenomics Across the Adult Lifespan 13.4 Dementia vs. Delirium vs. Depression: Differential Diagnostics & Management 13.5 Falls, Mobility Impairment, Pressure Injury Prevention & Palliative Care Transitions
14 Chapter 14: Gynecologic & Women's Health
14.1 Contraceptive Management, Emergency Contraception & Preconception Counseling 14.2 Perimenopause, Menopause & Hormone Replacement Therapy (HRT) 14.3 Gynecologic Infections (Vaginitis, PID), Abnormal Uterine Bleeding & Cervical Cancer Screening (USPSTF/ASCCP)
15 Chapter 15: Plan-of-Care Process: Behavior Change, Education & Care Coordination
15.1 Behavioral Change: Motivational Interviewing, Models & Theories 15.2 Patient Education, Shared Decision-Making, Referrals, Care Coordination & Plan Reassessment
16 Chapter 16: APRN Professional Practice, Ethics, Policy & Quality Improvement
16.1 APRN Scope of Practice, Consensus Model, Collaborative Practice & Credentialing 16.2 Bioethics, Informed Consent, Advance Directives & Surrogate Decision-Making 16.3 Environmental & Social Determinants of Health, Health Equity & Culturally Responsive Care 16.4 Evidence-Based Practice (EBP), Quality Improvement (QI) Methodologies & Healthcare Economics
4.2 Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents
Key Takeaways Explain This Topic AI
The 2018 AHA/ACC Cholesterol Guidelines establish four primary statin benefit groups: (1) Clinical ASCVD (secondary prevention), (2) Severe primary hypercholesterolemia (LDL-C ≥190 mg/dL), (3) Diabetes mellitus in adults aged 40–75 with LDL-C 70–189 mg/dL, and (4) Primary prevention across 10-year ASCVD risk categories.
High-intensity statin therapy (Atorvastatin 40–80 mg or Rosuvastatin 20–40 mg) lowers LDL-C by ≥50%, while moderate-intensity statins lower LDL-C by 30–49%; high-intensity therapy is mandated for all patients with established clinical ASCVD (age ≤75) and primary LDL-C ≥190 mg/dL.
For intermediate-risk primary prevention patients (10-year ASCVD risk 7.5% to <20%) where treatment decisions remain uncertain, Coronary Artery Calcium (CAC) scoring provides definitive risk reclassification: a score of 0 favors withholding statins (unless smoking, DM, or strong family history), while CAC ≥100 or ≥75th percentile mandates immediate statin initiation.
Non-statin pharmacotherapy follows a strict evidence-based hierarchy: Ezetimibe is the first-line add-on agent when LDL-C remains above threshold on maximally tolerated statin therapy, followed by PCSK9 inhibitors (evolocumab, alirocumab) for very high-risk secondary prevention or familial hypercholesterolemia.
Severe hypertriglyceridemia (fasting triglycerides ≥500 mg/dL) necessitates immediate fibrate therapy (fenofibrate preferred over gemfibrozil), prescription omega-3 fatty acids (icosapent ethyl), and alcohol abstinence to prevent acute necrotizing pancreatitis before addressing LDL-C targets.
Last updated: August 2026
Dyslipidemia & ASCVD Risk Calculation, Statin Therapy & Non-Statin Agents
Atherosclerotic Cardiovascular Disease (ASCVD)—encompassing coronary heart disease, ischemic stroke, transient ischemic attack (TIA), and peripheral artery disease (PAD)—remains the leading cause of death in adults. Apolipoprotein B-containing lipoproteins, particularly Low-Density Lipoprotein Cholesterol (LDL-C) , penetrate injured arterial endothelium, undergo oxidative modification, trigger macrophage foam cell transformation, and drive progressive fibrofatty atheroma formation.
The 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol provides the clinical foundation for primary and secondary cardiovascular risk reduction. Board candidates must master the four statin benefit groups, 10-year ASCVD risk calculation, risk-enhancing factors, statin intensity stratifications, Coronary Artery Calcium (CAC) decision rules, non-statin add-on hierarchies, and the clinical management of statin-associated muscle symptoms (SAMS).
1. Lipoprotein Physiology, Lipid Panels & The Friedewald Equation
A standard fasting lipid profile measures Total Cholesterol (TC) , High-Density Lipoprotein Cholesterol (HDL-C) , and Triglycerides (TG) , while calculating Low-Density Lipoprotein Cholesterol (LDL-C) . +-----------------------------------------------------------------------------+
- | THE FRIEDEWALD EQUATION FOR LDL-C |
- | |
- | \text{LDL-C} = \text{TC} - \text{HDL-C} - \frac{\text{TG}}{5} |
- | |
- | * \frac{\text{TG}}{5} estimates Very Low-Density Lipoprotein (VLDL) cholesterol|
- | * VALIDITY CRITERION: Accurate ONLY when fasting Triglycerides < 400 mg/dL|
- | * LIMITATION: If TG >= 400 mg/dL, the Friedewald formula fails. |
- | The AGPCNP must order a DIRECT LDL-C assay. |
- +-----------------------------------------------------------------------------+
Clinical Lipid Fractions & Target Thresholds:
Lipid Fraction Optimal Level Borderline / High Clinical & Pathophysiological Significance
Total Cholesterol < 200 mg/dL <200\text{ mg/dL} < 200 mg/dL 200 – 239 (Borderline) 200–239\text{ (Borderline)} 200–239 (Borderline) ; ≥ 240 mg/dL (High) \ge 240\text{ mg/dL (High)} ≥ 240 mg/dL (High) Composite marker of circulating atherogenic and protective lipoproteins.
LDL-C < 100 mg/dL <100\text{ mg/dL} < 100 mg/dL (Primary); < 70 mg/dL <70\text{ mg/dL} < 70 mg/dL (Secondary/High Risk); < 55 mg/dL <55\text{ mg/dL} < 55 mg/dL (Very High Risk) 130 – 159 (Borderline) 130–159\text{ (Borderline)} 130–159 (Borderline) ; 160 – 189 (High) 160–189\text{ (High)} 160–189 (High) ; ≥ 190 mg/dL (Very High) \ge 190\text{ mg/dL (Very High)} ≥ 190 mg/dL (Very High) Primary atherogenic driver and primary target of therapeutic lipid lowering. Each 38.7 mg/dL 38.7\text{ mg/dL} 38.7 mg/dL ( 1 mmol/L 1\text{ mmol/L} 1 mmol/L ) reduction in LDL-C yields a ~21% reduction in major ASCVD events.
HDL-C ≥ 40 mg/dL \ge 40\text{ mg/dL} ≥ 40 mg/dL (Men); ≥ 50 mg/dL \ge 50\text{ mg/dL} ≥ 50 mg/dL (Women) < 40 mg/dL (Low/Risk Factor) <40\text{ mg/dL (Low/Risk Factor)} < 40 mg/dL (Low/Risk Factor) Mediates reverse cholesterol transport from peripheral tissues to liver. Low HDL-C is an independent ASCVD risk factor.
Triglycerides (TG) < 150 mg/dL <150\text{ mg/dL} < 150 mg/dL 150 – 199 (Borderline) 150–199\text{ (Borderline)} 150–199 (Borderline) ; 200 – 499 (High) 200–499\text{ (High)} 200–499 (High) ; ≥ 500 mg/dL (Very High) \ge 500\text{ mg/dL (Very High)} ≥ 500 mg/dL (Very High) Elevated TG reflects chylomicrons and VLDL remnants. Levels ≥ 500 mg/dL \ge 500\text{ mg/dL} ≥ 500 mg/dL (especially ≥ 1 , 000 mg/dL \ge 1,000\text{ mg/dL} ≥ 1 , 000 mg/dL ) trigger acute pancreatitis .
Non-HDL-C < 130 mg/dL <130\text{ mg/dL} < 130 mg/dL Calculated: Non-HDL = TC − HDL \text{Non-HDL} = \text{TC} - \text{HDL} Non-HDL = TC − HDL Captures all atherogenic apolipoprotein B-containing particles (LDL, VLDL, IDL, Lp(a)). Useful when TG are elevated.
2. 10-Year ASCVD Risk Estimation & Risk-Enhancing Factors
For primary prevention in adults aged 40 to 75 years without diabetes and with LDL-C 70–189 mg/dL, clinical decision-making begins by calculating the 10-Year ASCVD Risk using the Pooled Cohort Equations (PCE). Variables include age, sex, race, total cholesterol, HDL-C, systolic blood pressure, treatment for hypertension, diabetes status, and current smoking history. +-----------------------------------------------------------------------------+
- | 10-YEAR ASCVD RISK CATEGORIES (POOLED COHORT EQUATIONS) |
- | |
- | RISK CATEGORY 10-YEAR RISK SCORE PRIMARY CLINICAL RECOMMENDATION|
- | ----------------------------------------------------------------------- |
- | LOW RISK < 5.0% Lifestyle modification |
- | BORDERLINE RISK 5.0% to < 7.5% Risk discussion; consider |
- | moderate statin if risk |
- | enhancers present |
- | INTERMEDIATE RISK 7.5% to < 20.0% Moderate-intensity statin |
- | (target: 30-49% reduction)|
- | Consider CAC if uncertain |
- | HIGH RISK >= 20.0% High-intensity statin |
- | (target: >= 50% reduction)|
- +-----------------------------------------------------------------------------+
ASCVD Risk-Enhancing Factors:
When clinical judgment is borderline or intermediate, the presence of ASCVD Risk-Enhancing Factors favors initiating or intensifying statin therapy:
Family history of premature ASCVD (first-degree male relative < 55 <55 < 55 years, female relative < 65 <65 < 65 years).
Primary hypercholesterolemia (persistently elevated LDL-C 160 – 189 mg/dL 160–189\text{ mg/dL} 160–189 mg/dL or non-HDL 190 – 219 mg/dL 190–219\text{ mg/dL} 190–219 mg/dL ).
Metabolic Syndrome (presence of ≥ 3 \ge 3 ≥ 3 : increased waist circumference, TG ≥ 150 \text{TG} \ge 150 TG ≥ 150 , low HDL, BP ≥ 130 / 85 \text{BP} \ge 130/85 BP ≥ 130/85 , fasting glucose ≥ 100 \ge 100 ≥ 100 ).
Chronic Kidney Disease (eGFR 15 – 59 mL/min/1.73 m 2 15–59\text{ mL/min/1.73 m}^2 15–59 mL/min/1.73 m 2 with or without albuminuria; not treated with dialysis/transplant).
Chronic inflammatory conditions (Rheumatoid Arthritis, Systemic Lupus Erythematosus, Psoriasis, HIV/AIDS).
History of premature menopause (age < 40 <40 < 40 years) or pregnancy-associated conditions (Preeclampsia, Gestational Diabetes, low birth weight infant).
High-risk race/ethnicity (e.g., South Asian ancestry).
Persistently elevated inflammatory or lipid biomarkers:
High-sensitivity C-reactive protein ( hs-CRP ≥ 2.0 mg/L \text{hs-CRP} \ge 2.0\text{ mg/L} hs-CRP ≥ 2.0 mg/L )
Lipoprotein(a) ( Lp(a) ≥ 50 mg/dL \text{Lp(a)} \ge 50\text{ mg/dL} Lp(a) ≥ 50 mg/dL or ≥ 125 nmol/L \ge 125\text{ nmol/L} ≥ 125 nmol/L )
- Apolipoprotein B ( ApoB ≥ 130 mg/dL \text{ApoB} \ge 130\text{ mg/dL} ApoB ≥ 130 mg/dL )
- Ankle-Brachial Index ( ABI < 0.90 \text{ABI} < 0.90 ABI < 0.90 )
- 3. The Four Primary Statin Benefit Groups & Intensity Dosing
The 2018 AHA/ACC guidelines define four distinct patient populations where randomized clinical trial evidence demonstrates clear cardiovascular event reduction from statin therapy. +-----------------------------------------------------------------------------+
- | THE FOUR PRIMARY STATIN BENEFIT GROUPS |
- | |
- | GROUP 1: CLINICAL ASCVD (SECONDARY PREVENTION) |
- | - History of ACS, MI, Stable/Unstable Angina, Revascularization, Stroke, |
- | TIA, or Peripheral Artery Disease of atherosclerotic origin. |
- | - Age <= 75 years: HIGH-INTENSITY STATIN (Goal: >= 50% LDL-C reduction) |
- | - Age > 75 years: Moderate- or High-Intensity Statin |
- | - Very High-Risk ASCVD: If LDL-C >= 70 on max statin -> Add EZETIMIBE; |
- | If still >= 70 -> Add PCSK9 INHIBITOR |
- | |
- | GROUP 2: SEVERE PRIMARY HYPERCHOLESTEROLEMIA (LDL-C >= 190 mg/dL) |
- | - No risk score calculation needed; initiate HIGH-INTENSITY STATIN |
- | - If LDL-C remains >= 100 mg/dL on max statin -> Add EZETIMIBE |
- | |
- | GROUP 3: DIABETES MELLITUS IN ADULTS AGED 40-75 YEARS (LDL-C 70-189 mg/dL)|
- | - MODERATE-INTENSITY STATIN mandatory regardless of 10-year ASCVD score |
- | - HIGH-INTENSITY STATIN indicated if multiple ASCVD risk factors or |
- | 10-year ASCVD risk >= 20% |
- | |
- | GROUP 4: PRIMARY PREVENTION ACROSS LIFESPAN (AGED 40-75, LDL-C 70-189) |
- | - 10-Yr Risk >= 20% (High Risk) -> HIGH-INTENSITY STATIN |
- | - 10-Yr Risk 7.5% to <20% (Intermediate) -> MODERATE-INTENSITY STATIN |
- | - 10-Yr Risk 5% to <7.5% (Borderline) -> Discuss Moderate Statin if |
- | risk-enhancing factors present |
- +-----------------------------------------------------------------------------+
- Statin Intensity Stratification & Dosing Protocol
- Intensity Category Expected LDL-C Reduction Daily Dosing Regimens
- High-Intensity ≥ 50 % \ge 50\% ≥ 50% reduction Atorvastatin 40–80 mg ; Rosuvastatin 20–40 mg
Moderate-Intensity 30 – 49 % 30–49\% 30–49% reduction Atorvastatin 10–20 mg ; Rosuvastatin 5–10 mg ; Simvastatin 20–40 mg ; Pravastatin 40–80 mg ; Lovastatin 40 mg ; Fluvastatin XL 80 mg ; Pitavastatin 1–4 mg
Low-Intensity < 30 % <30\% < 30% reduction Simvastatin 10 mg ; Pravastatin 10–20 mg ; Lovastatin 20 mg ; Fluvastatin 20–40 mg
Important
Definition of Very High-Risk ASCVD: Very High Risk is defined as a history of multiple major ASCVD events (e.g., recent ACS within 12 months, history of MI, ischemic stroke, symptomatic PAD) OR 1 major ASCVD event PLUS multiple high-risk conditions (e.g., age ≥ 65 \ge 65 ≥ 65 , diabetes mellitus, hypertension, CKD, current smoking, persistently elevated LDL-C ≥ 100 mg/dL \text{LDL-C} \ge 100\text{ mg/dL} LDL-C ≥ 100 mg/dL , history of CHF). In these patients, the treatment threshold is LDL-C < 70 mg/dL \text{LDL-C} < 70\text{ mg/dL} LDL-C < 70 mg/dL (or < 55 mg/dL <55\text{ mg/dL} < 55 mg/dL per recent European updates); if LDL-C ≥ 70 mg/dL \text{LDL-C} \ge 70\text{ mg/dL} LDL-C ≥ 70 mg/dL on maximum tolerated statin, add Ezetimibe, followed by a PCSK9 inhibitor.
4. Coronary Artery Calcium (CAC) Scoring in Clinical Decision-Making
In intermediate-risk patients ( 7.5 % 7.5\% 7.5% to < 20 % <20\% < 20% ) or selected borderline-risk patients ( 5.0 % 5.0\% 5.0% to < 7.5 % <7.5\% < 7.5% ) where the decision to initiate statin therapy remains uncertain, non-contrast cardiac CT for Coronary Artery Calcium (CAC) scoring provides definitive risk reclassification. +-----------------------------------------------------------------------------+
- | CORONARY ARTERY CALCIUM (CAC) ALGORITHM |
- | |
- | [CAC SCORE = 0 (Agatston Units)] |
- | - Excellent 10-year prognosis; low ASCVD event rate |
- | - WITHHOLD OR DELAY STATIN THERAPY (reassess in 5 years) |
- | - EXCEPTIONS (statin still favored despite CAC=0): Current cigarette |
- | smokers, diabetes mellitus, family history of premature ASCVD |
- | |
- | [CAC SCORE = 1 to 99 (or < 75th percentile for age/sex)] |
- | - Favors initiating MODERATE-INTENSITY STATIN therapy |
- | - Especially recommended if patient is age >= 55 years |
- | |
- | [CAC SCORE >= 100 (or >= 75th percentile for age/sex)] |
- | - HIGH-RISK EQUIVALENT: INITIATE STATIN THERAPY IMMEDIATELY |
- | - Treat aggressively as high-risk primary prevention |
- +-----------------------------------------------------------------------------+
- 5. Non-Statin Lipid-Lowering Pharmacotherapy
When maximally tolerated statin therapy fails to achieve LDL-C goals, or in cases of complete statin intolerance, non-statin agents are added in a stepwise, evidence-based sequence. +-----------------------------------------------------------------------------+
- | NON-STATIN PHARMACOLOGIC ARSENAL |
- | |
- | [STEP 1: FIRST-LINE ADD-ON] ---> EZETIMIBE (10 mg daily) |
- | - Lowers LDL-C additional 15-20% |
- | - Inexpensive, oral, well-tolerated |
- | | |
- | v |
- | [STEP 2: SECOND-LINE ADD-ON] ---> PCSK9 INHIBITORS (Evolocumab/Alirocumab)|
- | - Lowers LDL-C additional 50-60% |
- | - Injectable subQ q2w or monthly |
- | | |
- | v |
- | [ALTERNATIVE & ADJUNCT AGENTS] |
- | - Bempedoic Acid (ACL inhibitor; liver-specific prodrug, no myopathy) |
- | - Bile Acid Sequestrants (Colesevelam; GI-bound, safe in pregnancy) |
- | - Fibrates (Fenofibrate; PPAR-alpha agonist, primarily lowers TG) |
- | - Omega-3 Fatty Acids (Icosapent Ethyl; lowers TG and ASCVD events) |
- +-----------------------------------------------------------------------------+
- Detailed Pharmacology of Non-Statin Agents
Drug Class & Agents Mechanism of Action Lipid Effects Clinical Indications & Exam Pearls
Cholesterol Absorption Inhibitor ; Ezetimibe (10 mg daily) Inhibits Niemann-Pick C1-Like 1 (NPC1L1) transporter at brush border of jejunum; reduces intestinal cholesterol absorption. ↓ \downarrow ↓ LDL-C 15 – 20 % 15–20\% 15–20% , mild ↑ \uparrow ↑ HDL, mild ↓ \downarrow ↓ TG. First-line add-on to statin (IMPROVE-IT trial). Excellent safety profile. Minimal drug interactions.
PCSK9 Inhibitors ; Evolocumab (140 mg SQ q2w); Alirocumab (75–150 mg SQ q2w) Monoclonal antibodies that bind and inactivate Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) , preventing LDL receptor degradation and massively increasing hepatic LDL clearance. ↓ \downarrow ↓ LDL-C 50 – 60 % 50–60\% 50–60% , ↓ \downarrow ↓ Lp(a) 25 – 30 % 25–30\% 25–30% . Very high-risk ASCVD or severe familial hypercholesterolemia uncontrolled on max statin + ezetimibe (FOURIER, ODYSSEY Outcomes trials). Adverse: Injection site reactions, flu-like symptoms.
ATP Citrate Lyase Inhibitor ; Bempedoic Acid (180 mg daily) Inhibits ATP citrate lyase upstream of HMG-CoA reductase in hepatic cholesterol synthesis pathway. ↓ \downarrow ↓ LDL-C 15 – 25 % 15–25\% 15–25% . Liver-specific prodrug: enzyme is absent in skeletal muscle , eliminating statin-like muscle pain (CLEAR Outcomes trial). Adverse: Hyperuricemia/gout, slight risk of tendon rupture.
Bile Acid Sequestrants (Resins) ; Colesevelam (3.75 g daily); Cholestyramine (4–16 g daily) Binds bile acids in intestine, interrupting enterohepatic circulation; upregulates hepatic LDL receptors. ↓ \downarrow ↓ LDL-C 15 – 30 % 15–30\% 15–30% , ↑ \uparrow ↑ Triglycerides 5 – 20 % 5–20\% 5–20% . Safe in pregnancy (non-absorbed). Decreases HbA1c in diabetes. CONTRAINDICATED if baseline TG ≥ 300 mg/dL \text{TG} \ge 300\text{ mg/dL} TG ≥ 300 mg/dL (worsens hypertriglyceridemia). Impairs absorption of fat-soluble vitamins (A, D, E, K), warfarin, and levothyroxine.
Fibric Acid Derivatives (Fibrates) ; Fenofibrate (48–145 mg daily); Gemfibrozil (600 mg BID) Activates Peroxisome Proliferator-Activated Receptor Alpha (PPAR- α \alpha α ) ; stimulates lipoprotein lipase (LPL) and fatty acid oxidation. ↓ \downarrow ↓ TG 30 – 50 % 30–50\% 30–50% , ↑ \uparrow ↑ HDL 10 – 20 % 10–20\% 10–20% , variable LDL effect. First-line for severe hypertriglyceridemia ( TG ≥ 500 mg/dL \text{TG} \ge 500\text{ mg/dL} TG ≥ 500 mg/dL ) to prevent pancreatitis. Fenofibrate is preferred with statins; Gemfibrozil is strictly contraindicated with statins (blocks statin glucuronidation, raising statin blood levels and triggering severe rhabdomyolysis).
Purified EPA Omega-3 ; Icosapent Ethyl (2 g BID with food) Highly purified ethyl ester of eicosapentaenoic acid (EPA); reduces hepatic VLDL synthesis and enhances TG clearance. ↓ \downarrow ↓ TG 20 – 30 % 20–30\% 20–30% . Indicated in adults with established ASCVD or DM + ≥ 2 \ge 2 ≥ 2 risk factors with fasting TG 135 – 499 mg/dL \text{TG } 135–499\text{ mg/dL} TG 135–499 mg/dL on statin (REDUCE-IT trial: 25% relative risk reduction in MACE). Caution: Slight increase in AFib risk.
6. Severe Hypertriglyceridemia Management & Pancreatitis Prevention
When fasting triglycerides reach or exceed 500 mg/dL 500\text{ mg/dL} 500 mg/dL (and especially > 1 , 000 mg/dL >1,000\text{ mg/dL} > 1 , 000 mg/dL ), chylomicrons saturate capillary circulation in the pancreas, releasing excessive free fatty acids that overwhelm albumin binding, causing direct pancreatic capillary and acinar cell necrosis ( Acute Hypertriglyceridemic Pancreatitis ). +-----------------------------------------------------------------------------+
- | HYPERTRIGLYCERIDEMIA CLINICAL MANAGEMENT PROTOCOL |
- | |
- | [FASTING TRIGLYCERIDES 150 - 499 mg/dL] (MILD TO MODERATE) |
- | - Primary goal: ASCVD Risk Reduction |
- | - Maximize lifestyle: Weight loss, eliminate refined sugars, reduce alcohol|
- | - Optimize Statin therapy -> Add Icosapent Ethyl if indicated (REDUCE-IT) |
- | |
- | [FASTING TRIGLYCERIDES >= 500 mg/dL] (SEVERE) |
- | - PRIMARY IMMEDIATE GOAL: PREVENT ACUTE PANCREATITIS |
- | - LDL-C lowering is secondary until TG < 500 mg/dL |
- | - STRICT DIETARY INTERVENTION: Very low-fat diet (< 15% total calories), |
- | complete abstinence from alcohol, avoid simple carbohydrates |
- | - INITIATE FIBRATE THERAPY IMMEDIATELY: Fenofibrate 145 mg daily |
- | - Consider adding Prescription Omega-3 Acid Ethyl Esters (4 g/day) |
- +-----------------------------------------------------------------------------+
- 7. Statin Safety, Muscle Symptoms (SAMS) & Monitoring Protocols
Statins (HMG-CoA reductase inhibitors) have an exceptional long-term safety profile. However, fear of side effects and Statin-Associated Muscle Symptoms (SAMS) represent the primary cause of medication non-adherence and discontinuation. +-----------------------------------------------------------------------------+
- | SPECTRUM OF STATIN-ASSOCIATED MYOPATHY |
- | |
- | [MYALGIA] (Common, 5-10%) |
- | - Muscle aches, soreness, stiffness, or weakness |
- | - Bilateral, proximal large muscle groups (thighs, calves, buttocks) |
- | - Creatine Kinase (CK) level is NORMAL |
- | |
- | [MYOSITIS / MYOPATHY] (Uncommon, <0.1%) |
- | - Muscle pain and weakness accompanied by ELEVATED CK (3x-10x ULN) |
- | |
- | [RHABDOMYOLYSIS] (Rare, 1 in 100,000) |
- | - Severe muscle necrosis with CK > 10x to > 40x ULN |
- | - Myoglobinuria ("tea-colored" / dark brown urine) |
- | - Acute kidney injury from myoglobin tubular precipitation |
- +-----------------------------------------------------------------------------+
Step-by-Step Clinical Protocol for SAMS Evaluation:
Baseline Assessment: Measure baseline ALT/AST and lipid panel prior to statin initiation. Routine baseline Creatine Kinase (CK) is not recommended unless the patient has pre-existing neuromuscular disease or takes interacting drugs.
Routine Surveillance: Recheck fasting lipid panel at 4 to 12 weeks post-initiation or dose adjustment to assess adherence and response, then every 3 to 12 months thereafter. Routine surveillance monitoring of liver function tests (LFTs) or CK in asymptomatic patients is not recommended.
Management of Reported Muscle Symptoms:
Step 1: Discontinue the statin temporarily (washout period of 2 to 4 weeks ) until muscle symptoms completely resolve.
Step 2: Check serum CK, creatinine, and urinalysis for myoglobin if symptoms are severe or urine is dark.
Step 3: Once symptoms have fully resolved, re-challenge the patient with the same statin at a lower dose or switch to an alternative statin with different pharmacokinetic properties:
Switch from a lipophilic statin (atorvastatin, simvastatin, lovastatin) to a hydrophilic statin (rosuvastatin, pravastatin), which has lower muscle tissue penetration.
Utilize non-daily or intermittent dosing (e.g., Rosuvastatin 5–10 mg orally two to three times per week) due to its long elimination half-life (19 hours).
Step 4: If patient cannot tolerate any daily or intermittent statin dose, classify as statin-intolerant and initiate Ezetimibe and/or Bempedoic Acid or a PCSK9 inhibitor .